The future of HER2-targeted therapy is promising, with ongoing research focused on improving existing treatments and developing new ones. Advances in molecular biology and genomics are leading to a better understanding of HER2-driven cancers and the discovery of novel therapeutic targets. Clinical trials are exploring various combinations of HER2-targeted drugs with other agents to overcome resistance and enhance efficacy.
